Achilles Therapeutics Reports Wider Q1 Loss
08:37 AM EDT, 05/11/2021 (MT Newswires) -- Achilles Therapeutics (ACHL) reported a wider Q1 net loss Tuesday of $8.38 per diluted share, compared with a loss of $6.13 a year earlier. Two analysts polled by Capital IQ expected a loss of $1.55.
The company reported no revenue for the quarter.
Cash and cash equivalents stood at $159.3 million as of March 31, the company said, and it anticipates its existing cash and cash equivalents plus the initial public offering proceeds are sufficient to fund its planned operations into the second half of 2023, including full funding of ongoing clinical trials.
Price: 13.40, Change: -0.77, Percent Change: -5.43